Physician profile
John William Valade
NPI 1487656195
$3,438.63
in general payments reported to CMS, 2019-2025
29 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $601 · 2021: $549 · 2022: $328 · 2023: $263 · 2024: $321 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $647.79 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $424.67 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.03 | 2019-2025 | Jardiance, Spiriva Respimat |
| Pfizer INC. | $307.93 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $226.43 | 2019-2025 | Zoryve |
| Amgen INC. | $224.27 | 2019-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $183.56 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $149.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $121.70 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.31 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.02 | 2019-2025 | Xifaxan |
| Lundbeck LLC | $82.56 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $67.34 | 2019-2025 | |
| Astellas Pharma US INC | $62.38 | 2019-2024 | Veozah |
| Optinose US, INC. | $53.36 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $49.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $38.20 | 2024-2025 | Cds - Mct/Cem Monitoring |
| Grifols USA, LLC | $27.66 | 2025 | Prolastin-C Liquid |
| Avanir Pharmaceuticals, INC. | $19.67 | 2021 | |
| Eisai INC. | $18.82 | 2021 | |
| Acadia Pharmaceuticals INC | $18.74 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.01 | 2019 | |
| Sumitomo Pharma America, INC. | $17.86 | 2024 | Gemtesa |
| Lilly USA, LLC | $16.22 | 2024 | Mounjaro |
| Almatica Pharma LLC | $14.38 | 2021 | |
| Hikma Pharmaceuticals USA | $13.95 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.11 | 2024 | Camzyos |
| Teva Pharmaceuticals USA, INC. | $12.05 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Valade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.